ESMO26: Iza-bren leads post-TKI ADCs on efficacy, but toxicity could decide
Arriving after rivals offering smaller PFS gains but fewer serious adverse events, iza-bren will need its early OS advantage to hold.
Arriving after rivals offering smaller PFS gains but fewer serious adverse events, iza-bren will need its early OS advantage to hold.